Literature DB >> 10362217

Lipid-lowering therapy for the primary prevention of coronary heart disease.

A M Gotto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10362217     DOI： 10.1016/s0735-1097(99)00114-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  6 in total

Review 1.  Developmental mechanisms involved in the primary prevention of atherosclerosis and cardiovascular disease.

Authors:  Claudio Napoli
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

Review 2.  Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.

Authors:  S G Rockson
Journal:  Curr Atheroscler Rep       Date:  2000-03       Impact factor: 5.967

Review 3.  Vascular biology, atherosclerosis, and implications for cardiac care.

Authors:  G S Berenson; S R Srinivasan; B Radhakrishnamurthy
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

4.  Reproducibility, accuracy and concordance of Accutrend Plus for measuring circulating lipid concentration in adults.

Authors:  Aldo Scafoglieri; Jonathan Tresignie; Steven Provyn; Jan Pieter Clarys; Ivan Bautmans
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

5.  Pain-to-hospital times, cardiovascular risk factors, and early intrahospital mortality in patients with acute myocardial infarction.

Authors:  Eliana Brković; Katarina Novak; Livia Puljak
Journal:  Ther Clin Risk Manag       Date:  2015-02-11       Impact factor: 2.423

6.  Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers.

Authors:  Sowmya Venkatasubramanian; Radzi Mohd Noh; Shruti Daga; Jeremy P Langrish; Nikhil V Joshi; Nicholas L Mills; Ethan Hoffmann; Eric W Jacobson; George P Vlasuk; Brian R Waterhouse; Ninian N Lang; David E Newby
Journal:  J Am Heart Assoc       Date:  2013-06-14       Impact factor: 5.501
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.